Ipamorelin Dosing Protocol: GH Secretagogue Research

Also known as: NNC 26-0161

hormonal

Research Reference Only

This information is for educational purposes only. Ipamorelin is not FDA approved for human use. The protocols listed are summaries of published research studies and do not constitute medical advice. Always consult a licensed healthcare provider.

Overview

Ipamorelin is a growth hormone secretagogue that selectively stimulates the pituitary gland to release growth hormone. It is one of the most selective GHRPs studied.

Mechanisms of Action

Selective GH release

Minimal cortisol/prolactin increase

Ghrelin receptor agonist

Preserves natural GH pulsatility

Research Protocols

The following protocols are summaries of published research studies. They are presented for educational purposes only and do not constitute medical advice.

Protocol Name	Source	Dose	Frequency	Duration	Route	Evidence	Link
GH Release Study	clinical trial	100 μg	3x daily	4 weeks	Subcutaneous	human

Important Warnings

Safety Considerations

Hormone modulation requires monitoring
Not for unsupervised use